Financing ·
On July 28, 2026, Onconetix, Inc. entered into a securities purchase agreement to issue and sell 37,812 shares of…
ONCOOnconetix, Inc.
On July 28, 2026, Onconetix, Inc. entered into a securities purchase agreement to issue and sell 37,812 shares of Series F convertible preferred stock for an aggregate price of $30,249,600. The preferred stock has a stated value of $1,000 per share and converts at an initial price of $0.9767 per common share. Concurrently, the company established a committed equity line of credit allowing up to $750 million in future common stock issuances, subject to Nasdaq limits. A $30 million commitment fee was paid toward the PIPE purchase price. Onconetix is a clinical-stage biotechnology company focused on developing cancer immunotherapies.